Patient Forum: CAR T-Cell Therapy & Scleroderma - Today and Future (2024)

These sessions will explore the historical work on immunological reset for treatment resistance, B cell depletion therapy alongside CAR T therapy, the use of natural killer cells engineered to target CD19, and precision immunotherapies.
Presented by Peter Merkel, MD (Professor of Medicine and Epidemiology and Chief of the Division of Rheumatology, University of Pennsylvania School of Medicine) Max Konig, MD (Assistant Professor of Medicine, Johns Hopkins University of Medicine) Peter Maag, PhD (Chief Executive Officer, Kyverna), and David Shook, MD (Chief Medical Officer, Nkarta).
This session was originally presented on June 3, 2024, as part of the 3rd annual SRF Patient Forum, “Collaborating for a Cure.”
Learn more at www.srfcure.org

[@lillyrocks2011]

I hope we can get better treatments (more accessible and not only for diffuse Scleroderma but for all the types of antibodies with Scleroderma), and something directly for our skin, to stop the skin tightening, and hopefully a cure. 🙏🏽🕯️💗

[@SRFCURE]

Thanks for your comment, Lilly. The Scleroderma Research Foundation is committed to helping advance research that can improve treatments and bring us closer to a cure for scleroderma.

[@lillyrocks2011]

@@SRFCURE Thank you 🙏🏼 hopefully soon. This is such a really really a cruel disease. God bless all the scientifics doing research. Hopefully we can get treatments that really stop it. And can find the cause. 🙏🏼 Thank you. 💗